Table 4.
Results of collaborative study for the anti-lethal titer and anti-hemorrhagic titer determination
| Test | Anti-lethal titer (U/vial) | Anti-hemorrhagic titer (U/vial) | ||||
|---|---|---|---|---|---|---|
| 1a | 2b | 3c | 1a | 2b | 3c | |
| 1 | 2778 | 3678 | 2887 | 2456 | 3111 | 3640 |
| 2 | 3000 | 3537 | 2778 | 2638 | 3515 | 2616 |
| 3 | 3000 | 2900 | 3000 | 2956 | 3111 | 2957 |
| 4 | 2887 | 2900 | 3117 | 2638 | 3111 | 2651 |
| 5 | 2887 | 3152 | 3117 | 2992 | 3500 | 2505 |
| 6 | 2887 | 3609 | 2494 | 3515 | ||
| 7 | 2887 | 3961 | 2962 | 3500 | ||
| 8 | 2778 | 3777 | 2669 | 3111 | ||
| 9 | 3117 | 3678 | 2983 | 3500 | ||
| 10 | 2887 | 3537 | 2937 | 3500 | ||
| Common potency | 2909 | 3455 | 2997 | 2765 | 3342 | 2847 |
| 95% Confidence interval | 2837–2984 | 3195–3735 | 2798–3168 | 2614–2924 | 3198–3492 | 2362–3431 |
| Coefficients of variation | 3.50 | 11.00 | 5.00 | 7.84 | 6.16 | 15.00 |
| General common potency | 3131 | 3000 | ||||
aNational Institute of Food and Drug Safety Evaluation (NIFDS), Korea
bKorea Vaccine co., Korea
cNational Institute of Infectious Diseases (NIID), Japan